Quantcast
Home > Quotes > AGIO

Agios Pharmaceuticals, Inc. Common Stock (AGIO) Quote & Summary Data

AGIO 
$66.47
*  
3.17
4.55%
Get AGIO Alerts
*Delayed - data as of Nov. 19, 2018  -  Find a broker to begin trading AGIO now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    AGIO Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
104
Today's High / Low
$ 69.945 / $ 66.08
Share Volume
398,537
50 Day Avg. Daily Volume
484,268
Previous Close
$ 69.64
52 Week High / Low
$ 99.8242 / $ 51.62
Market Cap
3,867,136,594
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -6.26
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1.28

Intraday Chart

Shares Traded

Share Volume:
398,537
50 Day Avg. Daily Volume:
484,268

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -6.26

Trading Range

The current last sale of $66.47 is 28.77% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 69.945 $ 99.8242
 Low: $ 66.08 $ 51.62

ETFs with AGIO as a Top 10 Holding*

Weighting ETF Name (Symbol) 100-Day Price Change (%)
293% ALPS Medical Breakthroughs ETF (SBIO) -3.24 (-8.84%)
3.6% First Trust Amex Biotech Index Fund (FBT) -1.22 (-0.89%)
0% AGFiQ U.S. Market Neutral Size Fund (SIZ) -0.28 (-1.40%)
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.

Company Description (as filed with the SEC)

Item 1. Business We are a biopharmaceutical company committed to the fundamental transformation of patients' lives through scientific leadership in the field of cellular metabolism, with the goal of making transformative, first- or best-in-class medicines. Our therapeutic areas of focus are cancer and rare genetic diseases, or RGDs, which are diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. Most RGDs are often associated with severe or life-threatening features. The incidence of a single RGD can vary widely but is generally very infrequent, usually equal to or less than one per 100,000 births. In both areas of cancer and RGDs, we are seeking to unlock the biology of cellular metabolism as a platform to create transformative therapies. Our first commercial cancer product is IDHIFA┬«.  ... More ...  


Risk Grade

Where does AGIO fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 69.07
Open Date:
Nov. 19, 2018
Close Price:
$ 66.47
Close Date:
Nov. 19, 2018

Consensus Recommendation

Analyst Info



Another Bailout?? Why is the SEC boosting big banks and HFT's bottom lines?
x